NCT04675372

Dexmedetomidine Facilitate Analgesia

Based on the Real-time Monitoring of Nociceptive Index, Dexmedetomidine as a Neuraxial Adjuvant Facilitate Analgesia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 181 (actual)
• Sponsor: China International Neuroscience Institution · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive substances and further interrupting the spinal neuron-glia cross talk and regulating the nociceptive transmission under chronic pain condition. in this study, the analgesic efficacy of Dexmedetomidine was evaluated by a new non-invasive nociceptive index (qNOX). In this study, Anagel6000 analgesia monitor was used to quantitatively compare the analgesic efficacy of Dexmedetomidine compared with Midazolam.

Detailed description

Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive substances and further interrupting the spinal neuron-glia cross talk and regulating the nociceptive transmission under chronic pain condition. in this study, the analgesic efficacy of Dexmedetomidine was evaluated by a new non-invasive nociceptive index (qNOX). In this study, Anagel6000 analgesia monitor was used to quantitatively compare the analgesic efficacy of Dexmedetomidine compared with Midazolam.

Conditions

• Lower Limb Fracture
• Nerve Block

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
DRUG	Midazolam	Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam

Timeline

• Start date: 2021-01-19
• Primary completion: 2021-08-01
• Completion: 2021-08-03
• First posted: 2020-12-19
• Last updated: 2021-08-05

Locations

1 site across 1 country: China